Non-alcoholic Steatohepatitis Biomarkers Market Size & Growth Forecast 2027–2036, By Segments (Type, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Non-alcoholic Steatohepatitis Biomarkers Market size was more than USD 2.5 billion in 2026 and is set to grow at a 19.38% CAGR between 2027 and 2036, crossing USD 14.7 billion by 2036. The industry revenue for 2027 is assessed at USD 2.91 billion.
Get more details on this report
Request Free Sample ReportNon-alcoholic Steatohepatitis Biomarkers Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 56.60% of the market in 2026, supported by advanced diagnostic infrastructure, strong biomarker validation efforts, and broad integration into clinical research and specialist care.
- Asia Pacific is forecast to grow at a 25.19% CAGR as healthcare access expands, liver disease awareness improves, and demand rises for biomarker-based testing in clinical and research settings.
Segment Momentum
- Serum Biomarkers captured 33.07% of the market in 2026 because blood-based testing supports routine monitoring, large-scale patient evaluation, and practical use across clinical and research settings.
- Diagnostic Labs are the fastest-growing end users as biomarker testing increasingly shifts toward scalable clinical evaluation and routine patient identification and follow-up.
Market Expansion Drivers
- Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers.
- Advancements in serum-based and imaging diagnostics improving disease detection accuracy.
- Expanding pharma and CRO adoption supporting personalized liver disease treatment development.
Leading Market Participants
- Top companies in the non-alcoholic steatohepatitis biomarkers market include Siemens Healthineers AG (Germany), GENFIT S.A. (France), BioPredictive S.A. (France), Quest Diagnostics Incorporated (United States), Laboratory Corporation of America Holdings (United States), AstraZeneca PLC (United Kingdom), Pfizer Inc. (United States), Bristol-Myers Squibb Company (United States), Prometheus Laboratories Inc. (United States), Meridian Bioscience, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.5 billion
- 2027 Estimated Market Size: USD 2.91 billion.
- Projected Market Size: USD 14.7 billion by 2036
- Growth Forecast: 19.38% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Serum Biomarkers (Type) | Pharma & CRO Industry (End Use)
- Emerging Opportunity Segment: Hepatic Fibrosis Biomarkers (Type) | Diagnostic Labs (End Use)
Market Growth Drivers and Industry Trends
Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers
The increasing burden of non-alcoholic steatohepatitis is creating a greater need for reliable approaches to identify disease earlier and assess progression without relying solely on invasive procedures, supporting the non-alcoholic steatohepatitis biomarkers market growth. NASH can develop alongside metabolic conditions and may progress toward more serious liver complications, making timely identification important for patient management. Biomarkers that can help indicate liver injury, inflammation, fibrosis, or disease progression offer clinicians additional information for evaluating patients and monitoring changes over time. Growing awareness of metabolic liver disease is also increasing interest in diagnostic approaches that can be incorporated into routine clinical assessment without requiring invasive tissue sampling.
Advancements in serum-based and imaging diagnostics improving disease detection accuracy
Progress in serum biomarker development and imaging-based assessment is strengthening the ability to identify and characterize liver abnormalities, contributing to greater utilization within the non-alcoholic steatohepatitis biomarkers market. Improved diagnostic approaches can provide clinicians with complementary information regarding hepatic inflammation, fibrosis, fat accumulation, and other disease characteristics. Serum-based testing can support repeat assessment through minimally invasive sampling, while advanced imaging technologies can provide detailed information about liver condition and structural changes. Combining these approaches with clinical evaluation can improve disease stratification and monitoring, particularly for patients who require ongoing assessment of liver health.
Expanding pharma and CRO adoption supporting personalized liver disease treatment development
Pharmaceutical companies and contract research organizations are increasingly incorporating biomarker strategies into liver disease research to improve patient selection, disease characterization, and treatment-response assessment, creating new demand within the non-alcoholic steatohepatitis biomarkers market. Biomarkers can assist clinical development teams in identifying appropriate patient populations and evaluating biological responses during drug development programs. Their use can also support more refined disease segmentation, enabling researchers to investigate differences in disease progression and treatment response among patient groups. As drug developers pursue more targeted approaches to metabolic and liver disorders, validated biomarker tools become increasingly relevant across clinical research, trial monitoring, and treatment-development workflows.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growing prevalence of NASH and liver diseases | 7.50% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Technological advancements in biomarker development | 7.70% | Medium term (2–5 yrs) | North America, Asia Pacific | Low | Moderate |
| Expansion of clinical trials and research in emerging markets | 7.70% | Long term (5+ yrs) | Asia Pacific, Latin America | Low | Slow |
| Rising NASH prevalence driving demand for early non-invasive diagnostic biomarkers | 2.50% | High | North America, Europe | High | Near Term |
| Advancements in serum-based and imaging diagnostics improving disease detection accuracy | 2.10% | High | North America, Asia Pacific | High | Mid Term |
| Expanding pharma and CRO adoption supporting personalized liver disease treatment development | 1.80% | Moderate | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the non-alcoholic steatohepatitis biomarkers market, North America accounted for the largest share in 2026 at 56.60%, supported by advanced clinical research capabilities, established diagnostic infrastructure, and increasing attention to liver diseases associated with metabolic health conditions. The region benefits from strong investment in biomedical research and the development of diagnostic technologies that can improve disease identification and patient monitoring. Growing recognition of the need for non-invasive approaches to assess liver health is encouraging interest in biomarker-based testing, particularly as healthcare providers seek alternatives to more invasive diagnostic procedures. Collaboration among clinical research institutions, diagnostic laboratories, and healthcare systems is also supporting the development and adoption of more sophisticated biomarker applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, propelled by improving healthcare infrastructure, rising awareness of liver health, and increasing demand for advanced diagnostic solutions. Changing dietary patterns, urbanization, and the growing burden of metabolic disorders are encouraging greater attention to early detection and disease management. Expansion of clinical research capabilities and diagnostic laboratory networks is improving access to specialized testing, while investments in healthcare modernization are creating favorable conditions for biomarker adoption. Increasing physician awareness of non-invasive diagnostic approaches and the gradual integration of advanced molecular and laboratory technologies into clinical practice are expected to strengthen regional demand.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Validation FocusGermany emphasizes clinically validated non-alcoholic steatohepatitis biomarkers to improve diagnostic confidence and patient management. Hospitals and research institutions are supporting standardized testing approaches alongside therapeutic development programs.
France 🇫🇷
Integrated Liver DiagnosticsFrance is incorporating non-alcoholic steatohepatitis biomarkers into broader liver disease management strategies. Healthcare providers are evaluating non-invasive diagnostic tools that improve monitoring while supporting more personalized treatment decisions.
Italy 🇮🇹
Diagnostic Pathway EnhancementItaly is strengthening the use of non-alcoholic steatohepatitis biomarkers within hepatology services to improve diagnostic workflows. Growing collaboration between laboratories and clinicians supports wider evaluation of biomarker-based testing solutions.
Japan 🇯🇵
Early Detection StrategyJapan is promoting non-alcoholic steatohepatitis biomarker development to strengthen early disease detection and reduce reliance on invasive procedures. Diagnostic innovation is closely linked with precision medicine and routine clinical practice.
South Korea 🇰🇷
Translational Research PipelineSouth Korea is advancing non-alcoholic steatohepatitis biomarkers through collaborative research between biotechnology firms and healthcare institutions. Commercial priorities include improving assay performance and supporting patient stratification for clinical studies.
United States 🇺🇸
Precision Diagnostic AdoptionThe U.S. continues expanding non-alcoholic steatohepatitis biomarker adoption as healthcare providers seek non-invasive methods for liver disease assessment. Clinical research, pharmaceutical development, and diagnostic laboratories are accelerating biomarker validation and integration.
Segment Leadership and Growth Trends
Non-alcoholic Steatohepatitis Biomarkers Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Serum Biomarkers (Largest Segment) vs Hepatic Fibrosis Biomarkers (Fastest-Growing Segment)
Serum biomarkers segment dominated the non-alcoholic steatohepatitis biomarkers market, accounting for the largest share of 33.07% in 2026. Its leading position is supported by the convenience of blood-based testing, which enables minimally invasive assessment and can be integrated into routine diagnostic and disease-monitoring workflows. Serum-based biomarkers also offer practical advantages for repeated evaluation, supporting their use across screening, clinical assessment, and treatment monitoring. Growing emphasis on earlier identification and non-invasive evaluation of liver-related conditions further strengthens demand for accessible biomarker approaches.
Hepatic fibrosis biomarkers are expected to represent the fastest-growing segment, supported by increasing attention to fibrosis assessment as an important component of disease progression evaluation. These biomarkers can help characterize the extent of liver tissue changes without relying exclusively on invasive assessment methods, making them valuable for clinical decision-making and ongoing monitoring. Their expanding relevance in patient stratification and disease management is expected to encourage broader adoption across diagnostic and research applications.
End Use Segment Analysis: Pharma & CRO Industry (Largest Segment) vs Diagnostic Labs (Fastest-Growing Segment)
The pharma & CRO industry segment held the largest share of the non-alcoholic steatohepatitis biomarkers market in 2026, reflecting the substantial role of biomarker technologies in pharmaceutical research and outsourced clinical development activities. Biomarkers support patient characterization, clinical trial design, treatment-response evaluation, and the assessment of disease progression, making them valuable throughout drug development programs. The growing need for reliable disease-monitoring tools and biomarker-driven research workflows reinforces demand from pharmaceutical and contract research organizations.
Diagnostic labs are emerging as the fastest-growing segment as healthcare systems place greater emphasis on accessible and scalable diagnostic approaches for liver-related disorders. Diagnostic laboratories can incorporate biomarker testing into established workflows, enabling broader patient evaluation and supporting physicians in disease assessment and monitoring. Increasing preference for non-invasive diagnostic methods is further strengthening the role of laboratories in expanding biomarker utilization beyond research-focused applications.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, Others | Serum Biomarkers | Hepatic Fibrosis Biomarkers |
| End Use | Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes | Pharma & CRO Industry | Diagnostic Labs |
Competitive Landscape and Market Positioning
Leading companies in the non-alcoholic steatohepatitis biomarkers market:
1. Siemens Healthineers AG (Germany)
2. GENFIT S.A. (France)
3. BioPredictive S.A. (France)
4. Quest Diagnostics Incorporated (United States)
5. Laboratory Corporation of America Holdings (United States)
6. AstraZeneca PLC (United Kingdom)
7. Pfizer Inc. (United States)
8. Bristol-Myers Squibb Company (United States)
9. Prometheus Laboratories Inc. (United States)
10. Meridian Bioscience Inc. (United States)
The non-alcoholic steatohepatitis biomarkers market is advancing due to growing demand for early and accurate liver disease diagnostics. Continuous research is enabling discovery of more precise biomarker panels for improved clinical assessment. Collaborative development efforts are enhancing diagnostic tool integration, while new testing solutions are improving accessibility and accuracy. These developments are strengthening innovation in the biomarkers market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Siemens Healthineers AG (Germany) | |||||||
| GENFIT S.A. (France) | |||||||
| BioPredictive S.A. (France) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Laboratory Corporation of America Holdings (United States) | |||||||
| AstraZeneca PLC (United Kingdom) | |||||||
| Pfizer Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Prometheus Laboratories Inc. (United States) | |||||||
| Meridian Bioscience Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| SomaLogic | Jul-24 | SomaLogic introduced new protein biomarkers for Non-alcoholic Steatohepatitis (NASH), providing mechanistic and clinical insights into acetyl-CoA carboxylase (ACC). The development strengthens non-invasive diagnostic capabilities by advancing biomarker-based approaches for disease identification and progression assessment in liver disease management. |
| Gilead Sciences | Feb-24 | Gilead Sciences completed a USD 4.3 billion acquisition of CymaBay Therapeutics to expand its liver disease portfolio, including Seladelpar, a PPARδ agonist for primary biliary cholangitis. The transaction enhances Gilead’s positioning in hepatology-focused therapeutics relevant to NASH-related disease pathways. |
| GENFIT | Sep-20 | GENFIT signed a five-year exclusive licensing agreement with LabCorp for commercialization of its NIS4 blood-based molecular diagnostic technology for identifying NASH patients at risk of disease progression. The collaboration expands access to non-invasive biomarker-based testing across the U.S. and Canada. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Non-alcoholic Steatohepatitis Biomarkers Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Stage | Early-Stage Disease, Moderate Disease, Advanced Fibrosis, Cirrhosis |
| Sample Type | Blood & Serum, Plasma, Urine, Liver Tissue, Other Biological Samples |
| Clinical Application | Disease Diagnosis, Disease Staging, Fibrosis Assessment, Treatment Monitoring, Drug Development |
Non-alcoholic Steatohepatitis Biomarkers Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Biomarker Commercialization Roadmap |
|
| Diagnostic Ecosystem Assessment |
|
| Precision Medicine Opportunity Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the non-alcoholic steatohepatitis biomarkers market?
What is the forecasted size of the non-alcoholic steatohepatitis biomarkers industry?
How is rising NASH prevalence affecting demand for non-invasive biomarker-based diagnostics?
How are pharma and CRO activities shaping biomarker utilization in NASH clinical development?
Why do Serum Biomarkers hold the largest share of the non-alcoholic steatohepatitis biomarkers market?
Which end-use segment is growing the fastest in the non-alcoholic steatohepatitis biomarkers market?
Why is North America the leading market for non-alcoholic steatohepatitis biomarkers?
Why is Asia Pacific the fastest-growing region for non-alcoholic steatohepatitis biomarkers?
Who are the leading players in the non-alcoholic steatohepatitis biomarkers landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization